Hydroxychloroquine et insuffisance rénale chronique : cas clinique et revue de la littérature

In Algeria, the essentially hydroxychloroquine therapeutic protocol was adopted on March 23, 2020, to which patients with Covid-19 were put. This protocol have proved its effectiveness according to the cure rate of 98.2% on a total of 16000 treated cases. [1]. Hydroxychloroquine (HCQ) is preferred for its better expected tolerance, based on the publications of preliminary work by several teams that we analyzed previously with a further three months' follow-up. On the pharmaceutical level, we are interested in the pharmacology of this molecule and underline the interest of pharmacokinetic studies to define the optimal dosage regimen for patients with a particular status (Renal Insufficiency - Hepatic Insufficiency - Pregnancy) in COVID-19. On the basis of this work, we can suggest dose adjustments and optimize the administration schedule with therapeutic monitoring of drugs which must be carried out to personalize the individual dosage regimen. So, the role of the hospital pharmacist is essential in the context of the pandemic to optimize and modify practices by developing new prescription protocols while ensuring good management of adverse effects.